tiprankstipranks

Analyst Profile

Followed by 179 followers
.
Patrick Trucchio

Patrick Trucchio

H.C. Wainwright
Wall Street Analyst
#7,780 out of 7,963 Wall Street Analysts
#21,669 out of 22,261 experts

Success Rate

32%
92 out of 287 transactions made a profit

Average Return

-16.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Patrick Trucchio's trades since 2014 and holding each position for 1 Year would result in 32.06% of your transactions generating a profit, with an average return of -16.0% per rating.

Stock Rating Distribution

339Ratings
95.28% Buy
2.95% Hold
1.77% Sell
Distribution of Patrick Trucchio's ratings

Additional Information

Main Sector:Consumer Goods
Geo Coverage:
United StatesUS Market
CanadaCanadian Market
United KingdomUK Market

Best Rating

Stock:
F-Star Therapeutics, Inc.
(FSTX)
Rating:Buy
Date:May 17, 2022 - Jul 15, 2022
Return:+158.40%
The most profitable rating made by Patrick Trucchio

Patrick Trucchio's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
AVP
Avon Products
Dec 23, 2014
Sell
Downgraded
1Ratings
100%
+52.00%
Kimberly Clark
Dec 23, 2014
Buy
Upgraded
$125.00
(6.67% Upside)
1Ratings
100%
+11.10%
Verona Pharma
Feb 20, 2018
Buy
Initiated
$30.00
(214.14% Upside)
1Ratings
0%
-52.50%
Societal CDMO
Apr 19, 2018
Buy
Initiated
$21.25
(1288.89% Upside)
1Ratings
0%
-27.30%
Innoviva
Apr 19, 2018
Buy
Initiated
$22.00
(82.27% Upside)
1Ratings
0%
-19.20%
Ironwood Pharma
Apr 19, 2018
Buy
Initiated
$25.00
(135.18% Upside)
1Ratings
0%
-23.50%
Perrigo Company
Nov 13, 2018
Hold
Downgraded
$72.00
(96.67% Upside)
2Ratings
0%
-27.50%
Morphosys
Feb 28, 2019
Hold
Reiterated
€108.00
(499.80% Upside)
1Ratings
0.00%
MNKKQ
Mallinckrodt
Sep 11, 2019
Sell
Reiterated
$1.00
(4900.00% Upside)
5Ratings
100%
+72.35%
Enanta Pharmaceuticals
Sep 18, 2019
Buy
Reiterated
$130.00
(140.47% Upside)
3Ratings
0%
-37.85%
List of latest recommendations made by Patrick Trucchio. Click to expand and see Patrick Trucchio's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >